Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 18, 1999

View Archived Issues

Dusa updates Levulan PDT development

Endorex study shows immune response stimulation by ImmTher in human cancer cells

Immune Response reports data from phase I colon cancer vaccine study

Medco third quarter progress marked by initiation of phase II coronary diagnostic trial

Trega Biosciences and Novartis expand R&D collaboration

Antiviral advisory committee meets in early November to discuss NDA for anti-HIV drug

Alpha-glucosidase inhibition as a target for development of broad-based anti-hepatitis virus agents

Eisai allowed to market Alzheimer's drug in Japan

Ariad discloses a wide series of cellular signal transduction inhibitors

EPO receptor ligands unrelated to primary EPO structure patented by Chugai

Immunogenic compositions for the treatment or prevention of HPV infections from Cantab

Wyeth-Ayerst reports U.S. launch of immunosuppressant

Preclinical results indicate a new target for RP therapy: calcium channel blockade

American Cyanamid claims nonpeptide MMP/TACE inhibitors for wide range of indications

New treatments for schizophrenia in the pipeline at Merck

Inflazyme to commence phase Ib studies with new oral asthma therapy

RotaShield withdrawn from the market following reports of intussusception

Preclinical review of AR-R15896AR presented at recent symposium

Progress toward a universal flu vaccine?

Dopascan as a potential biomarker for Parkinson's disease; clinical results presented

KRP-297: a novel thiazolidinedione that improves impaired fatty acid oxidation

New treatment for GERD now available in U.S.

Neurocrine Biosciences' NBI-3001 granted fast track designation

Dura and Spiros initiate pivotal clinical program for Beclomethasone Spiros

Highlights from EASD annual meeting: DPP-IV inhibitor shows promise in type II diabetes

Lotronex NDA up for review next month by GI advisory committee

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...